MOUNTAIN VIEW, Calif., Nov. 4, 2010 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the third quarter ended September 30, 2010 after the NASDAQ Market closes on Monday, November 8, 2010. The company will discuss financial results and provide a business update through a conference call and an audio webcast at 1:30pm PT on the same day.
Date: November 8, 2010 Time: 4:30 PM ETListen via Internet: http://ir.vivus.com/ Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=45010&k=3A9FFFA4
Telephone: 877-359-2916 International: 224-357-2386VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA(R), which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
CONTACT: VIVUS, Inc. Timothy E. Morris, Chief Financial Officer 650-934-5200 The Trout Group Investor Relations: Brian Korb 646-378-2923 firstname.lastname@example.org